Norderstedt, March 27th, 2023. schülke joined the Science Based Targets Initiative (SBTi) in June 2022 with a clear focus on advancing its climate protection activities on the basis of the latest findings in climate science, thereby committing itself to meeting the targets of the Paris climate protection agreement. Now schülke has submitted its concrete targets to SBTi for validation. Verification of the targets is expected by the end of this year. The submission to SBTi was preceded by an intensive process and a comprehensive analysis of the global schülke ecological footprint for the year 2021; emissions in Scopes 1, 2 and 3 were recorded and evaluated and a baseline was established to track progress. Scope 1 is the direct emissions of a company, Scope 2 is indirect emissions from purchased energy, and Scope 3 the indirect emissions within the value chain. On this basis, schülke has developed targets up to the year 2030, which are now being validated by SBTi. "As in everything we do, we also strive for excellence in meeting climate targets,” said schülke CEO Stefan Kukacka about the milestone. “We were therefore happy to commit to the ambitious Science Based Targets initiative. The entire workforce in all regions around the world have been involved in collecting the data and developing our targets. We have thus initiated a change in our company. That is something to be proud of and of which we are all proud." SBTi is a collaboration between the Carbon Disclosure Project (CDP), the UN Global Compact, the World Resources Institute (WRI), and the World Wide Fund for Nature (WWF). The initiative defines best science-based practices and independently assesses relevant corporate targets. More than 4,600 companies worldwide are already working with SBTi. In addition to its commitment to clear climate targets, schülke is continuously reducing the use of energy and resources with the help of modern technologies in addition to further developing its product portfolio and making it more sustainable. Consistent quality and effectiveness of the products at the highest standard to ensure the safety of patients and healthcare professionals are a matter of course. Further information on schülke's commitment and goals in the area of sustainability can be found at: https://www.schuelke.com/de-de/ueber-uns/verantwortung/nachhaltigkeit.php Details of schülke's emission reduction targets will be posted on their website after verification by SBTi: https://sciencebasedtargets.org/
- CEO Stefan Kukacka: "Submitting our ambitious targets to SBTi is the strongest indicator of our environmental sustainability activities so far. Because we want to make the difference – and set a benchmark for sustainability in our industry."
- The schülke goals are science-based and follow a concrete timetable: reducing absolute greenhouse gas emissions in Scope 1 and 2 by 42 %, and in purchased goods and services in Scope 3 by 25 % by 2030.
- The schülke emission reduction targets have been submitted to the SBTi for validation. Validation of the targets by the SBTi is expected by the end of the year.
From left to right: Annett Keizer, ESG & Sustainability Manager; Florian Seja, Controlling; Dr Nicole Steinhorst, Director Scientific Medical & Clinical Affairs / Chief Sustainability Officer; Stefan Kukacka, Managing Director / Chief Executive Officer; Ingrid Breul-Husar, Corporate Communications Manager; Matthias Kallert, Team Lead Engineering. Not pictured: Steffen Bahns, Sourcing Manager Procurement.
Schülke & Mayr GmbH (schülke)
Schülke & Mayr GmbH, headquartered in Norderstedt near Hamburg, has been a global leader in the field of infection prevention and control for almost 135 years. Infectious agents know no borders - this has always been true and is all the more important in today's globalised world. Committed to the mission "We protect lives worldwide", schülke actively contributes to the safety and health protection of people with its strategic business fields Healthcare, Over the Counter (OTC) and Life Sciences. With strong brands such as octenisept®, kodan®, desderman® or microshield®, schülke is one of the international market leaders in the field of wound and mucous membrane antisepsis as well as hand and surface disinfection in German hospitals. People in more than 80 countries around the world rely on schülke products every day. With its wide range of high-quality and innovative products, expert advice and reliable service, schülke offers holistic concepts for infection treatment and prevention in professional healthcare, for end consumers and the pharmaceutical sector. schülke is present with more than 1,100 dedicated employees, over 20 subsidiaries and three production sites in Germany (schülke), France (Bioxal) and Brazil (Vic Pharma). In 2021 alone, schülke contributed to protecting patients and health care professionals in hospitals from infections with three billion product applications.
More about schülke at: www.schuelke.com